The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.
 
Courtney C Cavalieri
No Relationships to Disclose
 
Eric Swanson
No Relationships to Disclose
 
Jonathan R. Whisenant
No Relationships to Disclose
 
John R. Weis
No Relationships to Disclose
 
Glynn Weldon Gilcrease
No Relationships to Disclose
 
David D. Stenehjem
No Relationships to Disclose
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Blend Therapeutics; Foundation Medicine; Foundation Medicine; Guardant Health; Novartis; Novartis; Novartis
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); Labceutics (Inst); Labceutics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending: “Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase”. U.S. Patent No. WO 2012135800 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. US 8,703,767 B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - Guardant Health
 
Ignacio Garrido-Laguna
No Relationships to Disclose